Thousand Oaks biotech giant Amgen issued $5 billion in debt securities Feb. 21 set to mature over the next five to 30 years. In filings with the Securities and Exchange Commission, the company said it received $4.96 billion in net proceeds after underwriting discounts and expenses. The notes were issued under a shelf registration Amgen…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
